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OBJECTIVES: Chlorthalidone (CLD) and hydrochlorothiazide (HCTZ) are the two 
most widely used thiazide-type diuretics. This study compared patient 
characteristics for CLD and HCTZ. METHODS: Adult patients with a hypertension 
diagnosis (ICD-9 401-405) and ≥2 antihypertensive prescriptions, one of which is 
CLD or HCTZ, were identified in the MarketScan Databases (2003-2009). Patients 
switching from CLD to HCTZ, or vice versa, or taking both together were 
excluded from the study. Patients had continuous enrollment for ≥6 months 
prior to and after their first prescription of either study drug RESULTS: A total of 
15,219 and 890,272 patients were identified for the CLD and HCTZ groups 
(female: 52.0% vs. 55.2%, mean age: 59.7 vs. 58.6 years). Notably different rates 
(CLD vs. HCTZ) were observed for prior medical conditions gout (3.4% vs. 2.4%) 
and chronic kidney disease (6.2% vs. 3.6%), with less pertinent differences for 
coronary heart disease (17.1% vs. 15.3%), congestive heart failure (11.0% vs. 
10.0%), arrhythmia (12.5% vs. 11.2%), hyperlipidemia (46.7% vs. 44.0%) and 
diabetes (21.2% vs. 19.3%). The mean Charlson Comorbidity Index (CCI) scores for 
CLD group were 3.3 and 3.1 for HCTZ group. Higher proportions of CLD patients 
had previously used beta blockers (BB) (40.2% vs. 27.8%) and calcium channel 
blockers (CCB) (27.7% vs. 21.8%), a lower proportion had used angiotensin 
receptor blockers (ARB) (12.9% vs. 16.0%), and similar use was seen for 
angiotensin-converting enzyme inhibitors (ACEI) (25.9% vs 25.2%). CLD patients 
had higher rates of concurrent BB (33.9% vs. 23.3%) and CCB (24.3% vs. 17.8%) use. 
Slight differences in the rates of ARB (12.6% vs. 10.9%) and ACEI (22.3% vs. 21.0%) 
concurrent use were also observed. CONCLUSIONS: This research suggests 
similar patient profiles for CLD and HCTZ users with CLD users having a slightly 
more severe overall prior co-morbidity status and higher rates of prior and 
concurrent BB / CCB medication use.  
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OBJECTIVES: Ezetimibe or colesevelam are often used for treating 
hypercholesterolemia when statin therapy is insufficient or not well tolerated. 
Our study objective was to examine prevalence of concomitant statin use and 
associated factors among hypercholesterolemia patients newly treated with 
ezetimibe or colesevelam and associated factors. METHODS: This analysis 
evaluated a large health plan’s Commercial and Medicare Advantage claims data 
from January 1, 2008 to July 31, 2012. The first ezetimibe (excluding fixed 
combination therapy of ezetimibe/simvastatin) or colesevelam prescription fill 
date during this period was identified as the index date. Patients were assigned 
to either ezetimibe or colesevelam cohort based on the index drug and were 
required to have ≥2 consecutive prescriptions for the index drug and have at 
least six months and 12 months continuous enrollment before and after the 
index date, respectively. Prevalence of concomitant statin use was identified 
based on pharmacy claims. Patient demographics and clinical characterisitics 
were explored to examine the factors associated with concomitant statin use 
using multivariate logistic regression. RESULTS: A total of 679 colesevelam and 
1439 ezetimibe patients were included in this study. The concomitant use of 
statins was 24% among colesevelam and 50% among ezetimibe patients, 
respectively. After adjustment for patient demographics and comorbidities, 
ezetimibe patients were 3.2 times more likely than colesevelam patients to have 
concomitant statin use (OR=3.168, 95% CI: 2.573, 3.900, P<0.001). Other significant 
factors associated with higher concomitant statin use include: male gender 
(OR=1.296, 95%: 1.079, 1.558, P=0.006), presence of diabetes mellitus (OR=1.262, 
95% CI: 1.035, 1.539, P=0.021) and higher Charlson comorbidity score (OR=1.114, 
95% CI: 1.046, 1.187, P<0.001). CONCLUSIONS: In this claims data analysis, statins 
were administered along with ezetimibe more frequently than administered 
with colesevelam, which should be taken into account when evaluating 
effectiveness of ezetimibe versus colesevelam in the real-world treatment of 
hypercholesterolemia.  
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OBJECTIVES: Colesevelam HCl is approved as both a cholesterol-lowering and 
anti-diabetes mellitus agent with pregnancy category B. Ezetimibe is approved as 
a cholesterol-lowering agent with pregnancy category C. This study examined 
demographic and clinical characteristics of hypercholesterolemic patients newly 
treated with colesevelam HCl versus ezetimibe. METHODS: This retrospective 
observational study utilized claims data from a large national health plan, and 
identified either colesevelam HCl or ezetimibe pharmacy claims between 
January 1, 2006 and March 31, 2011 as the index drug and the first fill date as the 
index date. Inclusion criteria included patients 18 years or older, diagnosis for 
hypercholesterolemia, and at least 6 months (baseline) and 12 months (follow-
up) continuous enrollment before and after the index date, respectively. Patient 
demographic and clinical characteristics were identified from enrollment, 
medical and pharmacy claims data. Chi-square and t-tests were used to examine 
patient characteristic differences between two treatment cohorts. RESULTS: A 
total of 3,357 colesevelam HCl and 17,026 ezetimibe patients met inclusion 
criteria, and were included in this study. Mean age was 55 and 57 years for 
colesevelam HCl and ezetimibe patients, respectively. Compared to the 
ezetimibe cohort, colesevelam HCl patients had higher prevalence of type 2 
diabetes mellitus diagnosis (25% vs. 20%, p<0.001), and a larger proportion were 
female (56% vs. 45%, p<0.001). Baseline statin use was more common among 
ezetimibe patients than colesevelam patients (55% vs. 37%, p<0.001). 
CONCLUSIONS: Compared to ezetimibe, colesevelam HCl was administered to a 
greater percent of patients with type 2 diabetes mellitus and women, which may 
be related to colesevelam HCl’s approved use as an anti-diabetes mellitus drug, 
and its pregnancy category B status. The baseline statin use was less common 
among colesevelam HCI patients than ezetimibe patients. These differences 
should be taken into account when evaluating real-world effectiveness of the 
two therapies.  
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OBJECTIVES: To examine the demographic and clinical characteristics,  
and cardiovascular treatment in patients with high-risk vascular disease (HRVD). 
METHODS: A retrospective cohort study was conducted using a large employer-
based US administrative claims database. This study identified patients aged  
18 to 64 years who had HRVD (defined as cerebrovascular disease [CVD], 
coronary artery disease with diabetes [CADD], peripheral artery disease [PAD], or 
history of acute coronary syndrome [ACS] [≥30days through 365 days after 
discharge for ACS]) between October 1, 2008 and September 30, 2009,  
with minimum 12-month pre-index and 24-month post-index insurance 
eligibility. Data on patients’ baseline demographic characteristics, comorbidities, 
and medication use were examined and compared across groups with and 
without polyvascular disease. RESULTS: A total of 516,863 HRVD patients were 
identified. Their average age was 55.2 years and 54.8% were male. Among the 
identified patients, 56.3% had hypertension, 53.2% had hypercholesterolemia, 
and 46.3% had diabetes. Patients were generally undertreated with statins (38.7% 
HRVD; range: 29.2% CVD to 65.5% ACS), antiplatelets (16.5% HRVD; range: 9.0% 
CVD to 59.5% ACS), beta-blockers (29.2% HRVD; range: 19.2% CVD to 65.4% ACS), 
and other evidence-based risk reduction therapies. Patients with >1 affected 
artery bed (11%) were older (age: 54.9, 57.4, 58.4 for 1, 2, 3 affected disease beds), 
had higher cardiovascular risk factors (for 1, 2, 3 affected disease beds, 
hypertension: 54.1%, 73.1%, 82.6%; hypercholesterolemia: 51.5%, 66.2%, 71.5%; 
diabetes: 43.9%, 63.7%, 82.4%), and used more cardiovascular-related 
medications (statins: 37.3%, 49.5%, 55.4%; antiplatelets: 14.7%, 30.0%, 41.7%; beta-
blockers: 27.5%, 41.8%, 51.1%) compared to patients with only one affected 
disease bed (p<0.01). The average number of medications per patient was seven 
for HRVD patients, ranging from 5.7 for CVD patients to 13.3 for patients with 
ACS, CADD, CVD, and PAD (N=1,005). CONCLUSIONS: Classic cardiovascular risk 
factors are consistent and common in HRVD patients, but are undertreated in 
the US.  
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OBJECTIVES: Irrational use of antibiotic, which adds to the cost of treatment, is 
known to lead to resistant microorganisms. Antimicrobial resistance 
substantially adds the already high costs of health care; and, it increases patient 
morbidity and mortality. Aim of the present study is to compare antimicrobial 
utilization in Cardiac Intensive Care Unit (CCU) and Medical Intensive Care Unit 
(MICU) of a private tertiary care hospital. METHODS: This study was carried out 
in CCU and MICU of a private tertiary care hospital. The data on antimicrobial 
utilization was collected prospectively from CCU and MICU. The antimicrobial 
utilization pattern was assessed using Rational Pharmaceutical Management 
(RPM) indicators. RESULTS: A total of 325 patients’ data was analyzed in CCU and 
MICU (229 & 96, respectively). The average number of AMAs prescribed was 
found to be 1.8±0.06. The average number of AMAs prescribed in MICU (2.6±0.16) 
was higher than that prescribed in CCU (1.8±0.06). AMAs contributed to  
the extent of 14% and 21% of the total drugs prescribed in CCU and  
MICU, respectively. Cefuroxime, Ceftriaxone, Vancomycin, and 
Piperacillin+Tazobactum were the most commonly prescribed AMAs in CCU, 
while Penems, antifungals, Ceftriaxone, Piperacillin+Tazobactum and 
Metronidazole were the commonly prescribed AMAs in MICU. Of 586 AMAs 
prescribed in both the ICUs, 31.5% AMAs were prescribed from the National List 
of Essential Medicines 2011, India (NLEM-2011). 96/338 AMAs were prescribed in 
CCU and 89/248 in MICU from NLEM-2011. Only 4.3% of AMAs were prescribed by 
generic name. A total of 67% of parenteral AMAs were prescribed, of which 53% 
from CCU (338) and 85% from MICU (248). CONCLUSIONS: On the basis of RPM 
indicators computed in this study, there is a need to consolidate these early 
findings.  
